Product Revenues was Bnb Plus’s largest product and service line in fiscal 2025, bringing in $1.66M of $2.76M (60%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Clinical Laboratory Testing Services (Point-In-Time) | $20.80M | $15.23M | — | — | |||||
| Clinical Laboratory Testing Services (Over-Time) | $10.26M | — | — | — | |||||
| Clinical Laboratory Services (Over-Time) | — | — | — | — | |||||
| Mdx Test Kits & Supplies | — | — | — | — | |||||
| Product Revenues | — | $3.75M | $1.03M | $1.66M | |||||
| Revenuefromcontractwithcustomerincludingassessedtax | — | — | — | — | |||||
| Research & Development Services (Point-In-Time) | — | — | $622.48K | — | |||||
| Research & Development Services (Over-Time) | $1.18M | $843.17K | — | — | |||||
| Service Revenues | $2.40M | $3.01M | $1.41M | $1.11M | |||||
| Supply Chain | — | — | — | — | |||||
| Large Scale Dna Production | — | $1.31M | $1.17M | — | |||||
| Asset Marking | $1.07M | $623.62K | $18.88K | — | |||||
| Clinical Laboratory Service Revenues | — | — | — | — | |||||
| Total | $35.70M | $24.76M | $4.25M | $2.76M |
Bnb Plus brought in $2.76M from its two product and service lines in fiscal 2025, the year ended September 30, 2025. That is less than the $4.27M it reports by geography, so these lines do not cover all of its revenue. Product Revenues was the largest at $1.66M (60.0%), ahead of Service Revenues at $1.11M (40.0%).
Compared with fiscal 2024, Product Revenues grew 61.0% to $1.66M, while Service Revenues fell 21.3% to $1.11M. Some of that change comes from Bnb Plus regrouping its lines.
Bnb Plus stopped reporting Clinical Laboratory Testing Services (Point-In-Time) ($15.23M in fiscal 2023), Clinical Laboratory Testing Services (Over-Time) ($10.26M in fiscal 2022), Large Scale Dna Production ($1.17M in fiscal 2024) and three others as separate lines.
Asia & Other was Bnb Plus’s largest region in fiscal 2025, bringing in $2.04M of $4.27M (48%).
| Geography | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Americas | $35.09M | $24.45M | $1.90M | $2.02M | |||||
| United States | — | — | — | — | |||||
| Salesrevenuenet | — | — | — | — | |||||
| Revenuefromcontractwithcustomerincludingassessedtax | — | — | — | — | |||||
| Asia & Other | $350.77K | $1.77M | $1.98M | $2.04M | |||||
| Europe | $897.69K | $516.71K | $344.74K | $211.17K | |||||
| Total | $36.34M | $26.73M | $4.23M | $4.27M |
Bnb Plus brought in $4.27M from its three regions in fiscal 2025, the year ended September 30, 2025. That was up 1.1% from $4.23M in fiscal 2024. Asia & Other was the largest at $2.04M (47.8%), ahead of Americas at $2.02M (47.3%) and Europe at $211.17K (4.9%).
Compared with fiscal 2024, Americas grew fastest, up 6.2% to $2.02M, while Europe fell the most, down 38.7% to $211.17K. From fiscal 2022 to 2025, combined revenue from these regions fell from $36.34M to $4.27M, a compound annual decline of 51.0%. Asia & Other's share of the total rose from 1.0% to 47.8%.
Therapeutic Dna Production was Bnb Plus’s largest segment in fiscal 2025, bringing in $1.66M of $2.85M (58%).
| Statement Business Segments | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Mdx Testing Services | $31.96M | $22.51M | -$25.84K | — | |
| Dna Tagging & Security Products | $2.51M | $1.32M | $1.41M | $1.19M | |
| Therapeutic Dna Production | $878.71K | $1.12M | $1.12M | $1.66M | |
| Total | $35.35M | $24.94M | $2.50M | $2.85M |
Bnb Plus brought in $2.85M from its two segments in fiscal 2025, the year ended September 30, 2025. That is less than the $4.27M it reports by geography, so these segments do not cover all of its revenue. Therapeutic Dna Production was the largest at $1.66M (58.2%), ahead of Dna Tagging & Security Products at $1.19M (41.8%).
Compared with fiscal 2024, Therapeutic Dna Production grew 48.0% to $1.66M, while Dna Tagging & Security Products fell 15.4% to $1.19M. Some of that change comes from Bnb Plus regrouping its segments.
Bnb Plus (BNBX) reports its revenue by product and service, by geography and by statement business segments. In fiscal 2025, Product Revenues was its largest product and service line, bringing in $1.66M (60.0% of the total), followed by Service Revenues at $1.11M (40.0%).
Product Revenues was Bnb Plus' largest product and service line in fiscal 2025, bringing in $1.66M, or 60.0% of the $2.76M total across its two product and service lines.
Asia & Other was Bnb Plus' largest region in fiscal 2025, bringing in $2.04M, or 47.8% of the $4.27M total across its three regions.
Therapeutic Dna Production was Bnb Plus' largest segment in fiscal 2025, bringing in $1.66M, or 58.2% of the $2.85M total across its two segments.
Among Bnb Plus' regions that make up at least 2% of revenue, Americas grew fastest in fiscal 2025, up 6.2% from $1.90M to $2.02M.
Every figure comes from Bnb Plus' annual financial filings, as reported. Each line keeps the name Bnb Plus gives it, and years follow its fiscal calendar.
Bnb Plus' revenue by product and service goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.